Scientific Industries INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Scientific Industries reports a reduced net loss of $1.59 million for Q1 2026, driven by revenue growth and cost-cutting initiatives.
OTC.Pink
Scientific Industries reports a significant net income for Q3 2025 driven by the sale of its Genie product line, despite ongoing operational losses in continuing segments.
OTC.Pink
Scientific Industries, Inc. reported a wider net loss for Q2 2025 and announced the sale of its Genie Division assets for up to $11.1 million, while also completing a $1.55 million private placement.
OTC.Pink
Scientific Industries reports a net loss of $1.78 million for Q1 2025, slightly improved from the previous year, while acknowledging substantial doubt about its ability to continue as a going concern.
OTC.Pink
Scientific Industries saw a significant reduction in its loss from continuing operations in the third quarter of 2024, driven by cost reductions and increased revenue in both operating segments.
OTC.Pink
10-Q: Scientific Industries Reports Reduced Losses in Q2 2024 Amidst Strategic Cost-Cutting Measures
Scientific Industries, Inc. reports a reduced loss for the second quarter of 2024, driven by strategic cost reductions and despite a decrease in overall revenue.
OTC.Pink
10-Q: Scientific Industries Reports Q1 2024 Results with Reduced Losses Amidst Strategic Initiatives
Scientific Industries reported a net loss of $2.05 million for the first quarter of 2024, an improvement compared to the $2.37 million loss in the same period last year, driven by cost-cutting measures and increased bioprocessing revenue.